Alternative Donor Transplantation—“Mixing and Matching”: the Role of Combined Cord Blood and Haplo-Identical Donor Transplantation (Haplo-Cord SCT) as a Treatment Strategy for Patients Lacking Standard Donors?

Current Hematologic Malignancy Reports

Volumn 10, Issue 1, 2015, Pages

  Liu, Hongtao ^a   van Besien, Koen ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Haplo cord SCT; Reduced intensity conditioning; T cell depletion; Third party donor cells; Umbilical cord blood transplant

Indexed keywords

CHIMERA; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PROCEDURES; SURVIVAL RATE;

CHIMERISM; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84922572331     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0245-y     Document Type: Review

References (46)

1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.
2. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010;116(11):1839–48.
3. Schlenk RF, Dohner K, Mack S, Stoppel M, Kiraly F, Gotze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010;28(30):4642–8.
4. Walter RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia. 2010;24:1276–82.
5. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–48. Latest data on the likelihood to find a stem cell donor for different ethnicities from NMDP.
6. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2011;119:1972–80.
7. Fuchs E, O’Donnell PV, Brunstein CG. Alternative transplant donor sources: is there any consensus? Curr Opin Oncol. 2013;25(2):173–9.
8. Fernandez Vina M, Heslop HE, Barker JN. New approaches in alternative donor transplantation. Biol Blood Marrow Transplant. 2013;19(1 Suppl):S91–6.
9. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.
10. Symons HJ, Fuchs EJ. Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant. 2008;42(6):365–77.
11. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693–9.
12. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22):2276–85.
13. Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014;371(18):1685–94. Prospective randomized study to demonstate comparable outcomes after double cord and signle cord transplant in pediatric patients with hematologic cancers.
14. Ruggeri A, Sanz G, Bittencourt H, Sanz J, Rambaldi A, Volt F, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia. 2013;28(4):779–86.
15. Sanz J, Wagner JE, Sanz MA, DeFor T, Montesinos P, Bachanova V, et al. Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms. Biol Blood Marrow Transplant. 2013;19(12):1725–30.
16. Bautista G, Cabrera JR, Regidor C, Fores R, Garcia-Marco JA, Ojeda E, et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant. 2009;43(5):365–73.
17. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118(24):6438–45. First publication of RIC haplo-cord SCT in patients with hematologic malignancies.
18. Wang J, Zhan P, Ouyang J, Chen B, Zhou R, Yang Y. Unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients: a meta-analysis. Leuk Res. 2010;34(8):1018–22.
19. Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant. 2007;13(4):444–53.
20. Zhang H, Chen J, Que W. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients. Biol Blood Marrow Transplant. 2012;18(8):1164–73.
21. Brunstein CG. Umbilical cord blood transplantation for the treatment of hematologic malignancies. Cancer Control. 2011;18(4):222–36.
22. Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kao G, et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011;18(4):565–74.
23. Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011;17(9):1327–34.
24. Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008;14(3):282–9.
25. Chen YB, Aldridge J, Kim HT, Ballen KK, Cutler C, Kao G, et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2011;18(5):805–12.
26. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–8.
27. Solh M, Brunstein C, Morgan S, Weisdorf D. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. Biol Blood Marrow Transplant. 2011;17(5):710–6.
28. Ramirez P, Brunstein CG, Miller B, Defor T, Weisdorf D. Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival. Bone Marrow Transplant. 2011;46(7):981–6.
29. Ballen KK, Spitzer TR. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant. 2011;46(3):323–9.
30. Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood. 2011;115(4):757–65.
31. Dahlberg A, Delaney C, Bernstein ID. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood. 2011;117(23):6083–90.
32. Norkin M, Lazarus HM, Wingard JR. Umbilical cord blood graft enhancement strategies: has the time come to move these into the clinic? Bone Marrow Transplant. 2013;48(7):884–9.
33. Fernandez MN, Regidor C, Cabrera R, Garcia-Marco JA, Fores R, Sanjuan I, et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol. 2003;31(6):535–44.
34. Kwon M, Bautista G, Balsalobre P, Sanchez-Ortega I, Serrano D, Anguita J, et al. Haplo-Cord Transplantation Using CD34 Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders. Biol Blood Marrow Transplant. 2014. The latest update of the outcomes of the largest so far cohort of 132 patients underwent myeloablative haplo-cord SCT in three Spanish institutions.
35. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013;19(5):682–91. Excellent review article on the halpo-cord SCT including deep discussion of the underlying fetal immune characteristics.
36. Taskinen MH, Huttunen P, Niittyvuopio R, Saarinen-Pihkala UM. Coinfusion of mobilized hematopoietic stem cells from an HLA-mismatched third-party donor with umbilical cord blood graft to support engraftment. J Pediatr Hematol Oncol. 2014;36(8):e518–23.
37. Kwon M, Martinez-Laperche C, Balsalobre P, Serrano D, Anguita J, Gayoso J, et al. Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells. Bone Marrow Transplant. 2014;49(2):212–8. Characteristics of chimerism dynamics after myeloablative haplo-cord SCT, and prediction of successful engraftment or graft failure using the early chimerism dynamics.
38. Newell LF, Milano F, Nicoud IB, Pereira S, Gooley TA, Heimfeld S, et al. Early CD3 peripheral blood chimerism predicts the long-term engrafting unit following myeloablative double-cord blood transplantation. Biol Blood Marrow Transplant. 2012;18(8):1243–9.
39. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118(25):6691–7.
40. Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010;116(15):2839–46.
41. Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147(2):262–74.
42. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, et al. Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leuk Lymphoma. 2013;54(6):1242–9.
43. Sebrango A, Vicuna I, de Laiglesia A, Millan I, Bautista G, Martin-Donaire T, et al. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes. Best Pract Res Clin Haematol. 2010;23(2):259–74.
44. Kwon M, Balsalobre P, Serrano D, Pérez Corral A, Buà ± o I, Anguita J, et al. Single cord blood combined with HLA-mismatched third party donor cells: comparable results to matched unrelated donor transplantation in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant. 2013;19(1):143–9. In this retrospective analysis with relatively small patient number, comparable clinical outcomes were found between haplo-cord SCT and MUD SCT in high risk patients with hematologic disorders.
45. Rhodes J, van Besien K, Liu H, Gergis U, Tsai SB, Mayer S, et al. Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 502,014 2014-12-06 00:00:00. 1235- p.
46. Van Besien K, Artz AS, Zhang MJ, Cushing M, Wickrema A, Korman S, et al. Haplo + cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantation—a case-cohort analysis. J Clin Oncol. 2014;32:(5S,):abstr 7004.